Urticaria is complicated to diagnose by its symptomatic overlap with other skin conditions and the frequent misclassification ...

Sanofi and Regeneron's Dupixent (dupilumab) has been approved by the FDA for the treatment of chronic spontaneous urticaria (CSU), a condition that causes painful hives that often don't respond to ...

Novartis’ immunoglobulin E inhibitor Xolair has been a mainstay of treatment for chronic spontaneous urticaria (CSU) for many years, but the company says it has gone one better with new ...

Doctors say it's increasingly common for adults who've never had allergies to suddenly experience symptoms like sneezing, ...

Celldex’s cash runway extends into 2027, but potential delays or hurdles could necessitate earlier fundraising, exerting ...

Learn more about whether Alvotech or Kymera Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, ...

The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adults and adolescents with ...

Rilzabrutinib significantly reduces itch and hives in patients with chronic spontaneous urticaria unresponsive to ...

The FDA has approved Dupixent for the treatment of patients aged 12 years and older with CSU who remain symptomatic despite H1 antihistamine treatment.